Minghui Pharmaceutical, Shanghai, China
Dr. Guoqing Cao obtained his B.S. from Fudan University in 1987 and PhD in 1995 in biochemistry and did his postdoc training with Nobel Laureates Dr. Michael Brown, Dr. Joseph Goldstein and Dr. Helen Hobbs at University of Texas Southwestern Medical Center at Dallas. He then joined cardiovascular division of Lilly Research Laboratory of Eli Lilly & Company in 1999 as a senior biologist and was subsequently promoted to principle research scientist, director of dyslipidemia/atherosclerosis, research advisor and senior research advisor. He led the development of several clinical candidates including a couple that finished phase 2/3 studies and won the President Award in 2009. He joined Jiangsu Hengrui Medicine in early 2012 as a vice president that oversaw the discovery, preclinical development, translational medicine, external collaboration, business development, R&D strategy and portfolio management. In 2018, he founded Minghui Pharmaceutical that is primarily focused on the discovery and the development of both small and large molecule drugs. He has published more than 80 papers in peer-reviewed journals and given oral presentations in more than 60 universities and international meetings. He also has more than 40 patents that have been awarded or in application.